New “Trojan horse” obesity drug supercharges weight loss in early tests
Key takeaways
- M ller at Helmholtz Munich have developed a new strategy to treat obesity and type 2 diabetes.
- In laboratory tests, mice treated with this compound ate less food, lost more weight, and showed better blood-glucose control than those given standard comparison treatments.
- Modern incretin therapies, which mimic natural satiety and blood sugar signals (GLP-1/GIP), have significantly improved treatment options for obesity and type 2 diabetes.
Why this matters: new research or scientific developments with potential real-world impact.
Researchers led by metabolism expert Prof Timo D. M ller at Helmholtz Munich have developed a new strategy to treat obesity and type 2 diabetes. Their approach uses a specially designed hybrid molecule that takes advantage of the well-known GLP-1/GIP signalling pathway as a kind of entry point into cells. Once inside, it delivers an additional metabolic compound directly where it is needed.
In laboratory tests, mice treated with this compound ate less food, lost more weight, and showed better blood-glucose control than those given standard comparison treatments. The findings were published as a preclinical study in the journal Nature.
Modern incretin therapies, which mimic natural satiety and blood sugar signals (GLP-1/GIP), have significantly improved treatment options for obesity and type 2 diabetes. Still, researchers are looking for ways to enhance these therapies further. One goal is to add drugs that improve how cells respond to insulin, helping glucose move more efficiently from the bloodstream into tissues.